Efficacy of low dose of rituximab to treat systemic lupus erythematosus - Takeaways - MDSpire

Efficacy of low dose of rituximab to treat systemic lupus erythematosus

  • By

  • Yan Chen

  • Limei Xu

  • Yanqing Wang

  • Xuwei Yang

  • Wenzhong Que

  • June 16, 2026

  • 0 min

Share

  • 1

    This study compared the efficacy and safety of low-dose rituximab (RTX) and belimumab (BEL) in treating systemic lupus erythematosus (SLE).

  • 2

    A total of 117 SLE patients were analyzed, with 51 receiving low-dose RTX and 66 receiving BEL between January 2020 and June 2023.

  • 3

    Both treatments significantly improved disease activity and laboratory parameters, but BEL showed greater efficacy in reducing glucocorticoid dosage.

  • 4

    Low-dose RTX achieved an overall efficacy of 39.2%, while BEL had an efficacy of 57.6%, with both treatments having comparable safety profiles.

  • 5

    The study supports low-dose RTX as an effective treatment option for SLE, despite BEL demonstrating advantages in certain outcomes.

Original Source(s)

Efficacy of low dose of rituximab to treat systemic lupus erythematosus

  • by Yan Chen, Limei Xu, Yanqing Wang, Xuwei Yang, Wenzhong Que

  • June 16, 2026

Related Content

Using objective measures of physical activity, sleep, and breathing for disease profiling of patients with systemic lupus erythematosus and Sjögren's disease

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.